Submit Content
Get the latest delivered to your inbox
Privacy Policy

Healthy Climate, Healthy Lives: Fossil Fuel Free Operations

Published 09-30-21

Submitted by Biogen

Healthy Climate, Healthy Lives infographic

In September 2020, Biogen launched a a 20-year, $250m commitment to eliminate fossil fuel emissions from its operations by 2040 and advance action on the deeply interconnected challenges of climate, health and equity.

With this initiative, Biogen became the 1st Fortune 500 company to commit to going beyond net zero to become fossil fuel free. In keeping with our emphasis on transparency, this report provides highlights of Biogen’s progress toward our Science Based Target initiatives-approved goals and commitment to Business Ambition for 1.5°C.

As a company that cares deeply about human health, we recognize the importance of addressing the impacts of the climate crisis on our collective wellbeing and advancing diversity, equity and inclusion. We are pleased with all we have accomplished in the past year, even as Biogen employees around the world are coming together with renewed urgency to promote a world that is healthy, equitable and sustainable for all.

To learn more and read our one-year progress report, please visit biogen.com/hchl

Biogen Logo

Biogen

Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain. We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media - Twitter, LinkedIn, Facebook, YouTube.

More from Biogen

Join today and get the latest delivered to your inbox